TARSONS

Tarsons Products Share Price

₹301.85 -13.05 (-4.14%)

29 Mar, 2025 15:42

SIP TrendupStart SIP in TARSONS

Start SIP

Performance

  • Low
  • ₹300
  • High
  • ₹319
  • 52 Week Low
  • ₹280
  • 52 Week High
  • ₹544
  • Open Price₹315
  • Previous Close₹315
  • Volume88,045

Investment Returns

  • Over 1 Month -1.28%
  • Over 3 Month -28.93%
  • Over 6 Month -31.23%
  • Over 1 Year -23.31%
SIP Lightning

Smart Investing Starts Here Start SIP with Tarsons Products for Steady Growth!

Invest Now

Tarsons Products Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 53.7
  • PEG Ratio
  • -
  • Market Cap Cr
  • 1,606
  • P/B Ratio
  • 2.6
  • Average True Range
  • 18.16
  • EPS
  • 5.62
  • Dividend Yield
  • 0.7
  • MACD Signal
  • -6.94
  • RSI
  • 43.85
  • MFI
  • 33.13

Tarsons Products Financials

Tarsons Products Technicals

EMA & SMA

Current Price
₹301.85
-13.05 (-4.14%)
pointer
  • stock-down_img
  • Bearish Moving Average 16
  • stock-up_img
  • Bullish Moving Average 0
  • 20 Day
  • ₹313.20
  • 50 Day
  • ₹332.76
  • 100 Day
  • ₹362.27
  • 200 Day
  • ₹399.23

Resistance and Support

307.05 Pivot Speed
  • R3 333.40
  • R2 326.35
  • R1 314.10
  • S1 294.80
  • S2 287.75
  • S3 275.50

What's your outlook on Tarsons Products?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Tarsons Products manufactures plastic labware and scientific equipment for research and diagnostic labs. With five manufacturing facilities in India, it serves industries like healthcare, pharmaceuticals, and biotechnology, providing high-quality lab products to both domestic and international markets.

Tarsons Products has an operating revenue of Rs. 385.44 Cr. on a trailing 12-month basis. An annual revenue de-growth of -1% needs improvement, Pre-tax margin of 21% is great, ROE of 6% is fair but needs improvement. The company has a reasonable debt to equity of 17%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 24 which is a POOR score indicating inconsistency in earnings, a RS Rating of 31 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 97 indicates it belongs to a poor industry group of Medical-Research Eqp/Svc and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Tarsons Products Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-14 Quarterly Results & Others To consider other business matters. per share(100%)Final Dividend
2024-11-07 Quarterly Results
2024-08-14 Quarterly Results
2024-05-30 Audited Results & Final Dividend
2024-02-13 Quarterly Results

Tarsons Products F&O

Tarsons Products Shareholding Pattern

47.31%
0%
7.51%
15.37%
29.81%

About Tarsons Products

  • NSE Symbol
  • TARSONS
  • BSE Symbol
  • 543399
  • Chairman & Managing Director
  • Mr. Sanjive Sehgal
  • ISIN
  • INE144Z01023

Similar Stocks to Tarsons Products

Tarsons Products FAQs

Tarsons Products share price is ₹301 As on 29 March, 2025 | 15:28

The Market Cap of Tarsons Products is ₹1606 Cr As on 29 March, 2025 | 15:28

The P/E ratio of Tarsons Products is 53.7 As on 29 March, 2025 | 15:28

The PB ratio of Tarsons Products is 2.6 As on 29 March, 2025 | 15:28

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23